Compare Citigroup Inc. (C) vs TG Therapeutics Inc (TGTX) Price & Performance

Citigroup (C) trades at $137.93, up 2.0% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with Q2 2026 EPS beating estimates at $3.06 versus $2.65 expected, revenue growth trending upward from $85.21B in 2025 to $91.4B projected for 2026, and improving net income margins. Recent corporate developments include strategic hires and dividend declarations, while institutional sentiment remains positive with 59% buy ratings.

The outlook for C remains favorable with a consensus price target of $154.38 offering 12% upside potential. Key opportunities include continued earnings growth and efficiency gains from the transformation plan. Risks include volatile cash flows from operations and elevated debt levels, though the current valuation at P/E 14.63 appears reasonable relative to historical performance.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.